Skip to main content
Premium Trial:

Request an Annual Quote

William Castell, Matthias Mann, Steve Martin, Peter Juhasz, Kinneret Savitsky, Dorit Bitter, Michal Preminger, Russell Singleton, Peter Wilver, Theo Melas-Kyriazi, Christopher Steffen, Bruce Stillman, Thomas Kelly


William Castell this week was named vice chairman of the board of directors for General Electric, completing the terms of the acquisition of Amersham by GE. Castell, Amersham’s CEO, is president and chief executive officer of GE Healthcare, the entity that combines Amersham into GE.

Matthias Mann will move to Munich to become a director at the Max Planck Institute for Biochemistry, effective May 1, 2005. He is currently the director of the Center for Experimental Bioinformatics at the University of Southern Denmark in Odense.

Steve Martin has left his post as director of Applied Biosystems’ Discovery Proteomics Small Molecule research center in Framingham, Mass., “to pursue an opportunity with a small startup,” the company said last week. He is replaced by Peter Juhasz, who joined ABI in 1994.

Kinneret Savitsky, Dorit Bitter, and Michal Preminger will leave Compugen, the Tel Aviv-based company confirmed last week. Savitsky, who is vice president for biology R&D, and Bitter, who is vice president for computational life sciences R&D, will stay with the company for several months as Compugen seeks replacements, according to a company spokeswoman. Preminger is vice president for protein therapeutics, working out of Jamesburg, NJ.

Perlegen said last week that Russell Singleton has become its vice president for engineering and informatics. Previously, he was president of his own company, developing business and marketing strategies for early-stage biotechnology firms and semiconductor equipment companies. He also held several positions at KLA-Tencor. Prior to that, he led instrumentation and software development programs at Molecular Dynamics. Singleton holds a PhD and a master’s degree from the University of Illinois and a bachelor’s degree from the Pratt Institute.

Peter Wilver has been promoted to CFO at Thermo Electron, effective October 1, the Waltham, Mass.-based company said last week. He succeeds Theo Melas-Kyriazi, who will leave Thermo at the end of September “to pursue entrepreneurial opportunities.” Wilver is currently Thermo’s vice president of financial operations, a post he has held since 2000. Prior to that, he worked at Honeywell International.

Christopher Steffen joins the board of directors of Accelrys, the company said last week. He was vice-chairman and director of Citicorp until he retired in 1996. Steffen is a graduate of University of Michigan and Wayne State University.

Bruce Stillman and Thomas Kelly have jointly received the annual Alfred P. Sloan Jr. Prize, General Motors said last week. They share the $250,000 award, one of three prizes given annually by the General Motors Cancer Research Foundation, for their contributions to the understanding of DNA replications in eukaryotes. Stillman is the president and CEO of Cold Spring Harbor Laboratory in New York. He holds a bachelor’s degree from the University of Sydney and a doctorate from Australian National University. Kelly is the director of the Sloan-Kettering Institute in New York City. He holds a bachelor’s, an MD, and a PhD from Johns Hopkins University.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.